Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy

Ähnliche Einträge

• Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs
  von: Yuichi Hiyama, et al.
  Veröffentlicht: (2024)
• High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
  von: Emi Sometani, et al.
  Veröffentlicht: (2024)
• Natural killer group 2D‐major histocompatibility complex class I polypeptide‐related sequence A activation enhances natural killer cell‐mediated immunity against hepatocellular carcinoma: A review
  von: Jun Arai, et al.
  Veröffentlicht: (2024)
• Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs
  von: Takanori Suzuki, et al.
  Veröffentlicht: (2024)
• Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”
  von: Wei Huang, et al.
  Veröffentlicht: (2024)